NHE3/SLC9A3 Drug Discovery Landscape & Assay Solutions

  • By admin
  • 23 Aug 2026
  • Comments

Market Intelligence, Clinical Progress, and High-Purity Reagents for Gastrointestinal and Renal Disease Development.

TarMart Solution Ecosystem & Related Targets

Comprehensive reagent toolkit for NHE3/SLC9A3 drug discovery. Select your modality below:

Component / Network Product Description Product Link
Gene Delivery NHE3 (SLC9A3) Premade Lentivirus Particles / Promise-ORF. Full-length ORF for stable cell line construction. Essential for complex multi-pass membrane proteins. HEK293T Packaging, Endotoxin Controlled. View NHE3 Products
Antigen / Antigen Panel NHE3 Extracellular Loop Peptides / Proteins; NHE1 (SLC9A1) / NHE2 (SLC9A2) Isoform Proteins for selectivity counter-screening. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified by Mass Spec. View NHE3 Products; View NHE1 Products
Benchmark Ab Anti-NHE3 Control / Reference Antibody (Sequence Verified). Recombinant positive control for western blot, FACS, and flow cytometry. View NHE3 Products
Validator NHE3 siRNA Set (3 target-specific + 1 control). For knockdown verification, specificity checks, and functional baseline establishment. View NHE3 Products
Related Target A NHE1 (SLC9A1). Ubiquitous isoform; critical for cardiac safety selectivity screening and counter-screening for isoform selectivity. View NHE1 Products
Related Target B NHE2 (SLC9A2). Gastric-specific isoform; complementary GI target for pan-NHE or tissue-specific studies. View NHE2 Products
Related Target C GC-C (GUCY2C). Synergistic target for IBS-C and chronic constipation pathways. View GUCY2C Products
Related Target D SGLT2 (SLC5A2). Synergistic renal sodium handling pathway for combination CKD therapy. View SGLT2 Products
Critical Assay Challenge The TarMart Advantage (Technical Spec)
Multi-pass Membrane Conformation (12-TM) Lentivirus-mediated stable cell lines preserving native tertiary structure and glycosylation. HEK293 Expression System.
Isoform Cross-Reactivity / Selectivity (NHE1 vs NHE3 vs NHE2) Comprehensive ortholog and homolog (NHE1/2/3) protein panels with >95% purity; Sequence Verified by Mass Spec.
Functional Transport Assay (pH-recovery, sodium flux) Full-length membrane protein delivery for pH-recovery and sodium flux assays; Endotoxin <1 EU/μg.
Lack of Controls / False Positives in Functional Assays Validated control antibodies and full-length ORFs included; valid siRNA for specificity checks and basal activity knockdown.
Cross-species Evaluation (Cyno/Mouse) Cynomolgus and Mouse NHE3 ORF clones available; Theoretical MW validated.
Surface Expression Validation Anti-NHE3 antibodies (extracellular epitope) for Flow Cytometry confirmation of membrane localization.

Live NHE3/SLC9A3 R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

The race for NHE3-targeted therapeutics has shifted from systemic hypertension management to tissue-specific indications. Following Ardelyx's approval of Tenapanor for hyperphosphatemia (XPHOZAH®) and IBS-C (IBSRELA®), the competitive landscape is pivoting toward next-generation inhibitors with improved GI restriction and reduced off-target NHE1 activity. As first-generation small molecules mature, the next wave of R&D is exploring bifunctional degraders (PROTAC), isoform-selective biologics, and combination therapies for chronic kidney disease (CKD) progression, heart failure fluid overload, and specific IBS-C sub-populations. Key players include Ardelyx, AstraZeneca, and emerging biotechs focusing on GI-restricted inhibitors and bispecific approaches.

Competitive Modality & Indication Snapshot

Connect market trends to assay needs.

Modality Representative Players Key Indications Critical Assay Need (Why TarMart?)
Small Molecule Inhibitor Ardelyx, AstraZeneca Hyperphosphatemia, IBS-C, Hypertension Transport Inhibition Assay (need full-length membrane protein in cell-based format; selectivity against NHE1/2)
Peptide Inhibitors Academic / Biotech Fluid Overload in Heart Failure Functional Na+ Uptake Assays (need pure baseline cells)
Antisense / RNAi Preclinical Hypertension Knockdown Validation (need siRNA controls)
Bispecific / PROTAC Emerging Academic CKD (Combining NHE3 + SGLT2) Dual-Target Cell Lines (need NHE3 + SGLT2 lentivirus co-transduction)
Antibody / Antagonist Preclinical Biotech GI-selective Inflammation Extracellular Epitope Mapping (need native conformation cell lines)

Genetic Mutations and Functional Insights (DIAR8-Related)

The target NHE3 (SLC9A3, UniProt P48764) is associated with congenital sodium diarrhea type 8 (DIAR8). Three key mutations have been characterized:

  • p.? (uncertain significance; does not affect cell membrane localization; reduced function) – Evidence: UniProt VAR_076419.
  • p.? (decreases cell membrane expression; reduces Na+/H+ exchange activity) – Evidence: UniProt VAR_076420.
  • p.? (decreases cell membrane expression; strongly reduces Na+/H+ exchange activity) – Evidence: UniProt VAR_076421.

These mutations highlight the importance of membrane trafficking and transport activity in disease. TarMart offers lentivirus particles for wild-type and mutant NHE3 to facilitate functional studies and resistance mechanism research.

Related Targets for Cross-sell